Stanford

Laura Attardi

Catharine and Howard Avery Professor of the School of Medicine and Professor of Genetics

Radiation Oncology - Radiation and Cancer Biology

Curriculum Vitae available Online

CONTACT INFORMATION

- **Administrative Contact**

  Micah Kelly - Radiation & Cancer Biology Administrative Programs Lead

  Email mkelly3@stanford.edu

  Tel 650-736-4757

Bio

ACADEMIC APPOINTMENTS

- Professor, Radiation Oncology - Radiation and Cancer Biology
- Professor, Genetics
- Member, Bio-X
- Member, Maternal & Child Health Research Institute (MCHRI)
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Fellow, American Association for Cancer Research Academy (2024)
- Member, National Academy of Sciences (Elected April 2026)

LINKS

- My Lab Site: http://www.med.stanford.edu/attardilab.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

The observations that the p53 gene is mutated in at least half of all human cancers of a wide variety of types and that p53 null mice develop cancer at 100% frequency together underscore the critical role for p53 in tumor suppression. Wild-type p53 is a cellular stress sensor, responding to diverse insults such as DNA damage, hyperproliferative signals, and hypoxia by inducing growth arrest or apoptosis, responses thought to be important to tumor suppression. At the molecular level, p53 acts a transcription factor that activates gene expression programs to induce these different responses. Interestingly, in its capacity as a cellular stress sensor, p53 also plays physiological roles beyond tumor suppression as well as causing certain pathological effects. For example, p53 plays beneficial roles such as promoting fertility, and can promote detrimental phenotypes in certain situations such as the side effects of cancer therapies or developmental diseases. The overarching goal of our research is to better define the mechanisms by which the p53 protein promotes different responses in different settings, ranging from tumor suppression to responses to chemotherapeutics, using

the mouse as an in vivo model system, with the ultimate goal of gaining insight that may facilitate clinical advances in diagnosis, prognostication and therapy. We utilize a combination of mouse genetic, cell biological, biochemical, and genomic approaches to address understand how p53 acts mechanistically. We hope to decipher the transcriptional networks responsible for mediating p53 functions in different contexts, an understanding that will help us understand how to best promote the beneficial and minimize the detrimental effects of p53 in the clinic.

We have a number of specific areas of investigation, which include:

* Defining the transcriptional networks responsible for tumor suppression, using CRISPR/Cas9 and shRNA high-throughput genetic screening approaches

* Identifying p53-interacting partners by mass spectrometry approaches

* Elucidating the genes activated and repressed by p53 in diverse settings using genomic technologies such as ChIP-sequencing and RNA-sequencing, to understand how p53 drives different responses

* Identifying p53 inhibitors to find strategies to suppress the detrimental effects of p53 activation, such as during cancer therapy

* Understanding p53's role in developmental diseases such as CHARGE syndrome

* Characterizing p53-regulated noncoding RNAs and their roles in cancer

* Examining mechanisms of p53 gain-of-function properties in cancer

Teaching

COURSES

2025-26

- Cancer Biology Journal Club: CBIO 280 (Aut, Spr)
- Lecture Seminar Series in Cancer Biology Program: CBIO 245 (Aut, Win, Spr)

2024-25

- Cancer Biology Journal Club: CBIO 280 (Aut)
- Lecture Seminar Series in Cancer Biology Program: CBIO 245 (Aut, Win, Spr)

2023-24

- Cancer Biology Journal Club: CBIO 280 (Aut)
- Lecture Seminar Series in Cancer Biology Program: CBIO 245 (Aut, Win, Spr)

2022-23

- Cancer Biology Journal Club: CBIO 280 (Aut)
- Lecture Seminar Series in Cancer Biology Program: CBIO 245 (Aut, Win, Spr)

STANFORD ADVISEES

Doctoral Dissertation Reader (AC)

Gina Duronio, Kristle Garcia, Aswini Krishnan, Darren Lam, Paloma Ruiz, Arianna Silva-Torres, Christine Zhou, Ronghao Zhou

Postdoctoral Faculty Sponsor

Tianwei Chen, Sofia Ferreira, The Nguyen, Chunxiao Ren, Tianyu Zhao

Doctoral Dissertation Advisor (AC)

Camila Bolle, Kathryn Hanson, Jessica Mann, Arati Rajeevan

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Genetics (Phd Program)

Publications

PUBLICATIONS

- **Activating p53Y220C with a mutant-specific small molecule.** *Nature communications*
  Zhu, X., Byun, W. S., Pieńkowska, D. E., Nguyen, K. T., Wang, M., Nettles, S. A., Gourisankar, S., Phillips, N. A., Gerhartz, J., Geng, Q., Qiu, T., Zhong, J., Jiang, et al
  2026
- **p53: defender of lineage fidelity and foe of plasticity in cancer and regeneration.** *Trends in cancer*
  Attardi, L. D., Rajeevan, A.
  2026
- **Inactivation of CDKN2AARF Promotes p53-Independent Remodeling of the PDAC Tumor Microenvironment.** *Cancer research*
  Ferreira, S., Flowers, B. M., Choi, W. Y., Farina-Morillas, M., Gatto, A., Bhattacharyya, S., Boross, G., Hassan, G., Mulligan, A. S., Vogel, H., Wood, L. D., Weaver, V. M., Winslow, et al
  2026
- **Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.** *Nature medicine*
  Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., Trajkovic-Arsic, M., Gupta, A., Heid, et al
  2026
- **Merlin's disappearing act: NF2 loss conjures pancreatic cancer survival in the hostile tumor microenvironment.** *The Journal of clinical investigation*
  Ferreira, S., Attardi, L. D.
  2026; 136 (1)
- **Merlin's disappearing act: NF2 loss conjures pancreatic cancer survival in the hostile tumor microenvironment** *JOURNAL OF CLINICAL INVESTIGATION*
  Ferreira, S., Attardi, L. D.
  2026; 136 (1)
- **p53 drives lung cancer regression through a TSC2/TFEB-dependent senescence program.** *Cancer discovery*
  Wang, M., Bieging-Rolett, K. T., Kaiser, A. M., Brady, C. A., Lockhart, J. H., Ferreira, S., Nguyen, K. T., Rajeevan, A., Evans, S. A., Zhao, T., Raj, N., Elkrief, A., Tischfield, et al
  2025
- **The legacy of a gentleman scientist: Pierre Hainaut.** *Cell death and differentiation*
  Arnoult, C., Attardi, L. D., Batsheva, K., Blandino, G., Burns, K. H., Del Sal, G., Kirsch, D. G., Lane, D. P., Levine, A. J., Lozano, G., Malkin, D., Melino, G., Oren, et al
  2025
- **Inactivation of CDKN2A ^{ARF} promotes p53-independent remodeling of the PDAC tumor microenvironment**
  Ferreira, S., Flowers, B. M., Choi, W., Farina-Morillas, M., Gatto, A., Bhattacharyya, S., Boross, G., Hassan, G., Mulligan, A. S., Vogel, H., Wood, L. D., Weaver, V. M., Winslow, et al

AMER ASSOC CANCER RESEARCH.2025

- **Analysis of knockout mice reveals critical female-specific roles for the Hippo pathway component PTPN14.** *Genes & development*
  McCrea, E. M., Makrides, N., Tabata, T., Reineking, W., Vilches-Moure, J. G., Wang, M., Lake, J. S., Vogel, H., Howitt, B., Zhang, X., Attardi, L. D.
  2025

- **Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network.** *Cell death and differentiation*
  Boutelle, A. M., Mabene, A. R., Yao, D., Xu, H., Wang, M., Tang, Y. J., Lopez, S. S., Sinha, S., Demeter, J., Cheng, R., Benard, B. A., McCrea, E. M., Valente, et al
  2025

- **Disruption of Ataxia-telangiectasia mutated kinase enhances radiation therapy efficacy in spatially-directed diffuse midline glioma models.** *The Journal of clinical investigation*
  Mangoli, A., Valentine, V., Maingi, S., Wu, S. R., Liu, H. Q., Aksu, M., Jain, V., Foreman, B. E., Regal, J. A., Weidenhammer, L. B., Stewart, C. E., Guerra Garcia, M. E., Hocke, et al
  2025

- **Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics.** *Nature communications*
  Wang, J., Seo, J. W., Kare, A. J., Schneider, M., Pandrala, M., Tumbale, S. K., Raie, M. N., Engudar, G., Zhang, N., Guo, Y., Zhong, X., Ferreira, S., Wu, et al
  2024; 15 (1): 10751

- **Activating p53Y220C with a Mutant-Specific Small Molecule.** *bioRxiv : the preprint server for biology*
  Zhu, X., Byun, W. S., Pieńkowska, D. E., Nguyen, K. T., Gerhartz, J., Geng, Q., Qiu, T., Zhong, J., Jiang, Z., Wang, M., Sarott, R. C., Hinshaw, S. M., Zhang, et al
  2024

- **NF1 MUTATION IN OLIGODENDROCYTE PRECURSOR CELLS LEADS TO PRENEOPLASTIC LESION FORMATION IN THE BRAIN**
  Pan, Y., Hysinger, J., Yalcin, B., Lennon, J., Byun, Y., Raghavan, P., Schindler, N., Anastasaki, C., Chatterjee, J., Ni, L., Xu, H., Malacon, K., Jahan, et al
  OXFORD UNIV PRESS INC.2024

- **Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.** *Nature medicine*
  Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., Trajkovic-Arsic, M., Gupta, A., Heid, et al
  2024

- **Nf1 mutation disrupts activity-dependent oligodendroglial plasticity and motor learning in mice.** *Nature neuroscience*
  Pan, Y., Hysinger, J. D., Yalçın, B., Lennon, J. J., Byun, Y. G., Raghavan, P., Schindler, N. F., Anastasaki, C., Chatterjee, J., Ni, L., Xu, H., Malacon, K., Jahan, et al
  2024

- **p53 promotes revival stem cells in the regenerating intestine after severe radiation injury.** *Nature communications*
  Morral, C., Ayyaz, A., Kuo, H. C., Fink, M., Verginadis, I. I., Daniel, A. R., Burner, D. N., Driver, L. M., Satow, S., Hasapis, S., Ghinnagow, R., Luo, L., Ma, et al
  2024; 15 (1): 3018

- **Epigenetic priming targets tumor heterogeneity to shift transcriptomic phenotype of pancreatic ductal adenocarcinoma towards a Vitamin D susceptible state.** *Cell death & disease*
  He, B., Stoffel, L., He, C. J., Cho, K., Li, A. M., Jiang, H., Flowers, B. M., Nguyen, K. T., Wang, K. W., Zhao, A. Y., Zhou, M. N., Ferreira, S., Attardi, et al
  2024; 15 (1): 89

- **Targeting p53 gain-of-function activity in cancer therapy: a cautionary tale.** *Cell death and differentiation*
  Attardi, L. D., Boutelle, A. M.
  2023

- **NF1 MUTATION IN OLIGODENDROCYTE PRECURSOR CELLS INDUCES PRENEOPLASTIC LESIONS IN THE BRAIN**

Pan, Y., Hysinger, J., Yalcin, B., Lennon, J., Raghavan, P., Schindler, N., Anastasaki, C., Chatterjee, J., Mount, C., Nagaraja, S., Scheaffer, S., Attardi, L., Gutmann, et al
OXFORD UNIV PRESS INC.2023

- **p53 governs an AT1 differentiation programme in lung cancer suppression.** *Nature*
  Kaiser, A. M., Gatto, A., Hanson, K. J., Zhao, R. L., Raj, N., Ozawa, M. G., Seoane, J. A., Bieging-Rolett, K. T., Wang, M., Li, I., Trope, W. L., Liou, D. Z., Shrager, et al
  2023

- **Tissue-regeneration program underlies lung-cancer suppression** *NATURE*
  Attardi, L. D., Kaiser, A. M.
  2023

- **Multifaceted role for p53 in pancreatic cancer suppression.** *Proceedings of the National Academy of Sciences of the United States of America*
  Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., Wood, L. D., Attardi, L. D.
  2023; 120 (10): e2211937120

- **Understanding the Arf-p53 axis in PDAC suppression**
  Attardi, L. D., Flowers, B. M., Hanson, K., Mulligan, A. S., Ferreira, S., Bhattacharyya, S., Vogel, H., Wood, L. D., Sherman, M.
  AMER ASSOC CANCER RESEARCH.2022: 33-34

- **Characterizing acinar cell and ductal cell derived PDACs in mouse models**
  Ferreira, S., Flowers, B. M., Hanson, K. J., Gatto, A., Bhattacharyya, S., Sherman, M. H., Attardi, L. D.
  AMER ASSOC CANCER RESEARCH.2022: 40-41

- **The p53 Transactivation Domain 1-Dependent Response to Acute DNA Damage in Endothelial Cells Protects against Radiation-Induced Cardiac Injury.** *Radiation research*
  Kuo, H., Luo, L., Ma, Y., Williams, N. T., da Silva Campos, L., Attardi, L. D., Lee, C., Kirsch, D. G.
  2022

- **The Mettl3 epitranscriptomic writer amplifies p53 stress responses.** *Molecular cell*
  Raj, N., Wang, M., Seoane, J. A., Zhao, R. L., Kaiser, A. M., Moonie, N. A., Demeter, J., Boutelle, A. M., Kerr, C. H., Mulligan, A. S., Moffatt, C., Zeng, S. X., Lu, et al
  2022

- **The role of p53 in the development of pancreatic ductal adenocarcinoma.**
  Hanson, K. J., Flowers, B. M., Hughes, N., Vogel, H., Cong, L., Attardi, L. D.
  AMER ASSOC CANCER RESEARCH.2021: 58

- **A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications.** *Annual review of pathology*
  Wang, M., Attardi, L. D.
  2021

- **Zmat3 splices together p53-dependent tumor suppression** *MOLECULAR & CELLULAR ONCOLOGY*
  Bieging-Rolett, K. T., Attardi, L. D.
  2021

- **Zmat3 splices together p53-dependent tumor suppression.** *Molecular & cellular oncology*
  Bieging-Rolett, K. T., Attardi, L. D.
  2021; 8 (3): 1898523

- **An anterograde pathway for sensory axon degeneration gated by a cytoplasmic action of the transcriptional regulator P53.** *Developmental cell*
  Simon, D. J., Belsky, D. M., Bowen, M. E., Ohn, C. Y., O'Rourke, M. K., Shen, R., Kim, G., Pitts, J., Attardi, L. D., Tessier-Lavigne, M.
  2021; 56 (7): 976

- **Cell of Origin Influences Pancreatic Cancer Subtype** *CANCER DISCOVERY*
  Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., Attardi, L. D.
  2021; 11 (3): 660–77

- **Cell of Origin Influences Pancreatic Cancer Subtype.** *Cancer discovery*
  Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., Attardi, L. D.
  2021; 11 (3): 660-677

- **p53 and Tumor Suppression: It Takes a Network.** *Trends in cell biology*
  Boutelle, A. M., Attardi, L. D.
  2021

- **P53 orchestrates a complex symphony of cellular processes during oncosuppression** *MOLECULAR & CELLULAR ONCOLOGY*
  Valente, L. J., Attardi, L. D.
  2021

- **P53 orchestrates a complex symphony of cellular processes during oncosuppression.** *Molecular & cellular oncology*
  Valente, L. J., Attardi, L. D.
  2021; 8 (1): 1852066

- **p53 is a central regulator driving neurodegeneration caused by C9orf72 poly(PR).** *Cell*
  Maor-Nof, M. n., Shipony, Z. n., Lopez-Gonzalez, R. n., Nakayama, L. n., Zhang, Y. J., Couthouis, J. n., Blum, J. A., Castruita, P. A., Linares, G. R., Ruan, K. n., Ramaswami, G. n., Simon, D. J., Nof, et al
  2021

- **The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling.** *Nature communications*
  Moon, E. J., Mello, S. S., Li, C. G., Chi, J., Thakkar, K., Kirkland, J. G., Lagory, E. L., Lee, I. J., Diep, A. N., Miao, Y., Rafat, M., Vilalta, M., Castellini, et al
  2021; 12 (1): 4308

- **A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies.** *Developmental cell*
  Tiu, G. C., Kerr, C. H., Forester, C. M., Krishnarao, P. S., Rosenblatt, H. D., Raj, N., Lantz, T. C., Zhulyn, O., Bowen, M. E., Shokat, L., Attardi, L. D., Ruggero, D., Barna, et al
  2021

- **Puma- and Caspase9-mediated apoptosis is dispensable for p53-driven neural crest-based developmental defects.** *Cell death and differentiation*
  Bowen, M. E., Mulligan, A. S., Sorayya, A. n., Attardi, L. D.
  2021

- **Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.** *Human mutation*
  Fortuno, C., Lee, K., Olivier, M., Pesaran, T., Mai, P. L., de Andrade, K. C., Attardi, L. D., Crowley, S., Gareth Evans, D., Feng, B., Foreman, A. K., Frone, M. N., Huether, et al
  2020

- **Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program.** *Molecular cell*
  Bieging-Rolett, K. T., Kaiser, A. M., Morgens, D. W., Boutelle, A. M., Seoane, J. A., Van Nostrand, E. L., Zhu, C., Houlihan, S. L., Mello, S. S., Yee, B. A., McClendon, J., Pierce, S. E., Winters, et al
  2020; 80 (3): 452

- **Pilot study of loss of the p53/p63 target genePERPat the surgical margin as a potential predictor of local relapse in head and neck squamous cell carcinoma** *HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK*
  Holmes, B. J., von Eyben, R., Attardi, L. D., Kong, C. S., Le, Q., Nathan, C. O.
  2020

- **Pilot study of loss of the p53/p63 target gene PERP at the surgical margin as a potential predictor of local relapse in head and neck squamous cell carcinoma.** *Head & neck*
  Holmes, B. J., von Eyben, R., Attardi, L. D., Kong, C. S., Le, Q. T., Nathan, C. O.
  2020

- **Deconstructing the origins of PDAC development.**
  Flowers, B., Xu, H., Hanson, K., Curtis, C., Vogel, H., Wood, L., Attardi., L. D.
  AMER ASSOC CANCER RESEARCH.2020: 19

- **p53 deficiency triggers dysregulation of diverse cellular processes in physiological oxygen.** *The Journal of cell biology*

Valente, L. J., Tarangelo, A. n., Li, A. M., Naciri, M. n., Raj, N. n., Boutelle, A. M., Li, Y. n., Mello, S. S., Bieging-Rolett, K. n., DeBerardinis, R. J., Ye, J. n., Dixon, S. J., Attardi, et al
2020; 219 (11)

- **Deciphering the origins of PDAC development**
  Flowers, B., Xu, H., Hanson, K., Curtis, C., Vogel, H., Wood, L. D., Attardi, L. D.
  AMER ASSOC CANCER RESEARCH.2019

- **Elucidating the role of p53 in the cellular origins of pancreatic cancer development**
  Flowers, B. M., Xu, H., Hanson, K., Curtis, C., Vogel, H., Wood, L. D., Attardi, L. D.
  AMER ASSOC CANCER RESEARCH.2019

- **The Spatiotemporal Pattern and Intensity of p53 Activation Dictates Phenotypic Diversity in p53-Driven Developmental Syndromes.** *Developmental cell*
  Bowen, M. E., McClendon, J., Long, H. K., Sorayya, A., Van Nostrand, J. L., Wysocka, J., Attardi, L. D.
  2019

- **Genome Edited Human Hematopoietic Stem Cells Correct Lysosomal Storage Disorders: Proof-of-Concept and Safety Studies for Mucopolysaccharidosis Type I and Gaucher Disease**
  Gomez-Ospina, N., Scharenberg, S., Mostrel, N., Raj, N., Attardi, L., Khan, S., Tomatsu, S., Lee, C., Bao, G., Porteus, M. H.
  CELL PRESS.2019: 329

- **The role of p53 in developmental syndromes** *JOURNAL OF MOLECULAR CELL BIOLOGY*
  Bowen, M. E., Attardi, L. D.
  2019; 11 (3): 200–211

- **The role of p53 in developmental syndromes.** *Journal of molecular cell biology*
  Bowen, M. E., Attardi, L. D.
  2019

- **Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I.** *Nature communications*
  Gomez-Ospina, N. n., Scharenberg, S. G., Mostrel, N. n., Bak, R. O., Mantri, S. n., Quadros, R. M., Gurumurthy, C. B., Lee, C. n., Bao, G. n., Suarez, C. J., Khan, S. n., Sawamoto, K. n., Tomatsu, et al
  2019; 10 (1): 4045

- **SIDT2 RNA Transporter Promotes Lung and Gastrointestinal Tumor Development.** *iScience*
  Nguyen, T. A., Bieging-Rolett, K. T., Putoczki, T. L., Wicks, I. P., Attardi, L. D., Pang, K. C.
  2019; 20: 14–24

- **Siva plays a critical role in mouse embryonic development.** *Cell death and differentiation*
  Jacobs, S. B., Van Nostrand, J. L., Bowen, M. E., Baker, J. C., Attardi, L. D.
  2019

- **Single Cell Transcriptomics Reveal Abnormalities in Neurosensory Patterning of the Chd7 Mutant Mouse Ear.** *Frontiers in genetics*
  Durruthy-Durruthy, R., Sperry, E. D., Bowen, M. E., Attardi, L. D., Heller, S., Martin, D. M.
  2018; 9: 473

- **Single Cell Transcriptomics Revea Abnormalities in Neurosensory Patterning of the Chd7 Mutant Mouse Ear** *FRONTIERS IN GENETICS*
  Durruthy-Durruthy, R., Sperry, E. D., Bowen, M. E., Attardi, L. D., Heller, S., Martin, D. M.
  2018; 9

- **Mutations in PERP Cause Dominant and Recessive Keratoderma.** *The Journal of investigative dermatology*
  Duchatelet, S., Boyden, L. M., Ishida-Yamamoto, A., Zhou, J., Guibbal, L., Hu, R., Lim, Y. H., Bole-Feysot, C., Nitschke, P., Santos-Simarro, F., de Lucas, R., Milstone, L. M., Gildenstern, et al
  2018

- **Neat-en-ing up our understanding of p53 pathways in tumor suppression.** *Cell cycle (Georgetown, Tex.)*
  Mello, S. S., Attardi, L. D.
  2018

- **Understanding the role of the tumor suppressor p53 in pancreatic cancer development.**

Flowers, B. M., Garcia, P. B., Gruner, B. M., Winslow, M. M., Attardi, L. D.
AMER ASSOC CANCER RESEARCH.2018: 44–45

- **Deconstructing p53 pathways in tumor suppression.**
  Mello, S., Bieging-Rolett, K., Kaiser, A., Valente, E., Raj, N., McClendon, J., Flowers, B., Morgens, D., Bassik, M., Attardi, L.
  AMER ASSOC CANCER RESEARCH.2018: 17
- **Deciphering p53 signaling in tumor suppression** *CURRENT OPINION IN CELL BIOLOGY*
  Mello, S. S., Attardi, L. D.
  2018; 51: 65–72
- **Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders** *NATURE*
  Calo, E., Gu, B., Bowen, M. E., Aryan, F., Zalc, A., Liang, J., Flynn, R. A., Swigut, T., Chang, H. Y., Attardi, L. D., Wysocka, J.
  2018; 554 (7690): 112-+
- **p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells** *CELL REPORTS*
  Tarangelo, A., Magtanong, L., Bieging-Rolett, K. T., Li, Y., Ye, J., Attardi, L. D., Dixon, S. J.
  2018; 22 (3): 569–75
- **Deconstructing networks of p53-mediated tumor suppression in vivo** *CELL DEATH AND DIFFERENTIATION*
  Kaiser, A. M., Attardi, L. D.
  2018; 25 (1): 93–103
- **Deconstructing networks of p53-mediated tumor suppression in vivo.** *Cell death and differentiation*
  Kaiser, A. M., Attardi, L. D.
  2018; 25 (1): 93–103
- **Loss of PERP p53/p63 target gene may indicate tumorigenesis at the margin and local recurrence**
  Simmons, A., Kong, C., von Eyben, R., Attardi, L., Ma, X., Quynh-Thu Le, Nathan, C.
  AMER ASSOC CANCER RESEARCH.2017
- **Essential role for centromeric factors following p53 loss and oncogenic transformation** *GENES & DEVELOPMENT*
  Filipescu, D., Naughtin, M., Podsypanina, K., Lejour, V., Wilson, L., Gurard-Levin, Z. A., Orsi, G. A., Simeonova, I., Toufektchan, E., Attardi, L. D., Toledo, F., Almouzni, G.
  2017; 31 (5): 463-480
- **The p53 family members have distinct roles during mammalian embryonic development.** *Cell death and differentiation*
  Van Nostrand, J. L., Bowen, M. E., Vogel, H., Barna, M., Attardi, L. D.
  2017
- **The Transactivation Domains of the p53 Protein.** *Cold Spring Harbor perspectives in medicine*
  Raj, N., Attardi, L. D.
  2017; 7 (1)
- **Neat1 is a p53-inducible lincRNA essential for transformation suppression.** *Genes & development*
  Mello, S. S., Sinow, C. n., Raj, N. n., Mazur, P. K., Bieging-Rolett, K. n., Broz, D. K., Imam, J. F., Vogel, H. n., Wood, L. D., Sage, J. n., Hirose, T. n., Nakagawa, S. n., Rinn, et al
  2017; 31 (11): 1095–1108
- **A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer.** *Cancer cell*
  Mello, S. S., Valente, L. J., Raj, N. n., Seoane, J. A., Flowers, B. M., McClendon, J. n., Bieging-Rolett, K. T., Lee, J. n., Ivanochko, D. n., Kozak, M. M., Chang, D. T., Longacre, T. A., Koong, et al
  2017; 32 (4): 460–73.e6
- **ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells.** *Oncogene*
  Khan, I. A., Yoo, B. H., Masson, O., Baron, S., CORKERY, D., Dellaire, G., Attardi, L. D., ROSEN, K. V.
  2016; 35 (44): 5759-5769
- **An inducible long noncoding RNA amplifies DNA damage signaling.** *Nature genetics*

Schmitt, A. M., Garcia, J. T., Hung, T., Flynn, R. A., Shen, Y., Qu, K., Payumo, A. Y., Peres-da-Silva, A., Broz, D. K., Baum, R., Guo, S., Chen, J. K., Attardi, et al
2016; 48 (11): 1370-1376

- **p19(Arf) is required for the cellular response to chronic DNA damage.** *Oncogene*
  Bieging-Rolett, K. T., Johnson, T. M., Brady, C. A., Beaudry, V. G., Pathak, N., Han, S., Attardi, L. D.
  2016; 35 (33): 4414-4421

- **p73 anc FoxJ1: Programming Multiciliated Epithelia** *TRENDS IN CELL BIOLOGY*
  Jackson, P. K., Attardi, L. D.
  2016; 26 (4): 239–40

- **Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)** *AUTOPHAGY*
  Klionsky, D. J., Abdelmohsen, K., Abe, A., Abedin, M. J., Abeliovich, H., Arozena, A. A., Adachi, H., Adams, C. M., Adams, P. D., Adeli, K., Adhihetty, P. J., Adler, S. G., Agam, et al
  2016; 12 (1): 1-222

- **Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.** *Nature medicine*
  Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sánchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., Trajkovic-Arsic, M., Gupta, A., Heid, et al
  2015; 21 (10): 1163-1171

- **Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma** *NATURE MEDICINE*
  Mazur, P. K., Herner, A., Mello, S. S., Wirth, M., Hausmann, S., Sanchez-Rivera, F. J., Lofgren, S. M., Kuschma, T., Hahn, S. A., Vangala, D., Trajkovic-Arsic, M., Gupta, A., Heid, et al
  2015; 21 (10): 1163-?

- **The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.** *Cancer discovery*
  Van Nostrand, J. L., Brisac, A., Mello, S. S., Jacobs, S. B., Luong, R., Attardi, L. D.
  2015; 5 (6): 622-635

- **Integrative genomic analysis reveals widespread enhancer regulation by p53 in response to DNA damage** *NUCLEIC ACIDS RESEARCH*
  Younger, S. T., Kenzelmann-Broz, D., Jung, H., Attardi, L. D., Rinn, J. L.
  2015; 43 (9): 4447-4462

- **Cancer: A piece of the p53 puzzle.** *Nature*
  Bieging, K. T., Attardi, L. D.
  2015; 520 (7545): 37-38

- **p53 suppresses muscle differentiation at the myogenin step in response to genotoxic stress** *CELL DEATH AND DIFFERENTIATION*
  Yang, Z. J., Broz, D. K., Noderer, W. L., Ferreira, J. P., Overton, K. W., Spencer, S. L., Meyer, T., Tapscott, S. J., Attardi, L. D., Wang, C. L.
  2015; 22 (4): 560-573

- **Analysis of p53 Transactivation Domain Mutants Reveals Acad11 as a Metabolic Target Important for p53 Pro-Survival Function.** *Cell reports*
  Jiang, D., Lagory, E. L., Kenzelmann Brož, D., Bieging, K. T., Brady, C. A., Link, N., Abrams, J. M., Giaccia, A. J., Attardi, L. D.
  2015; 10 (7): 1096-1109

- **Analysis of p53 Transactivation Domain Mutants Reveals Acad11 as a Metabolic Target Important for p53 Pro-Survival Function** *CELL REPORTS*
  Jiang, D., Lagory, E. L., Broz, D. K., Bieging, K. T., Brady, C. A., Link, N., Abrams, J. M., Giaccia, A. J., Attardi, L. D.
  2015; 10 (7): 1096-1109

- **Guilty as CHARGED: p53's expanding role in disease** *CELL CYCLE*
  Van Nostrand, J. L., Attardi, L. D.
  2014; 13 (24): 3798-3807

- **Inappropriate p53 activation during development induces features of CHARGE syndrome** *NATURE*

Van Nostrand, J. L., Brady, C. A., Jung, H., Fuentes, D. R., Kozak, M. M., Johnson, T. M., Lin, C., Lin, C., Swiderski, D. L., Vogel, H., Bernstein, J. A., Attie-Bitach, T., Chang, et al
2014; 514 (7521): 228-?

- **Inappropriate p53 activation during development induces features of CHARGE syndrome.** *Nature*
  Van Nostrand, J. L., Brady, C. A., Jung, H., Fuentes, D. R., Kozak, M. M., Johnson, T. M., Lin, C., Lin, C., Swiderski, D. L., Vogel, H., Bernstein, J. A., Attié-Bitach, T., Chang, et al
  2014; 514 (7521): 228-232
- **Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture** *NATURE MEDICINE*
  Li, X., Nadauld, L., Ootani, A., Corney, D. C., Pai, R. K., Gevaert, O., Cantrell, M. A., Rack, P. G., Neal, J. T., Chan, C. W., Yeung, T., Gong, X., Yuan, et al
  2014; 20 (7): 769-777
- **Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture.** *Nature medicine*
  Li, X., Nadauld, L., Ootani, A., Corney, D. C., Pai, R. K., Gevaert, O., Cantrell, M. A., Rack, P. G., Neal, J. T., Chan, C. W., Yeung, T., Gong, X., Yuan, et al
  2014
- **Unravelling mechanisms of p53-mediated tumour suppression** *NATURE REVIEWS CANCER*
  Bieging, K. T., Mello, S. S., Attardi, L. D.
  2014; 14 (5): 359-370
- **Illuminating p53 function in cancer with genetically engineered mouse models** *SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY*
  Garcia, P. B., Attardi, L. D.
  2014; 27: 74-85
- **Illuminating p53 function in cancer with genetically engineered mouse models.** *Seminars in cell & developmental biology*
  Garcia, P. B., Attardi, L. D.
  2014; 27: 74-85
- **Deconstructing p53 pathways in vivo**
  Brady, C. A., Broz, D., Jiang, D., Mello, S., Bieging, K., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Basak, S., Attardi, L. D.
  AMER ASSOC CANCER RESEARCH.2013
- **TRP53 activates a global autophagy program to promote tumor suppression.** *Autophagy*
  Kenzelmann Broz, D., Attardi, L. D.
  2013; 9 (9): 1440-1442
- **Not all p53 gain-of-function mutants are created equal.** *Cell death and differentiation*
  Mello, S. S., Attardi, L. D.
  2013; 20 (7): 855-857
- **Tumor suppression: p53 alters immune surveillance to restrain liver cancer.** *Current biology*
  Raj, N., Attardi, L. D.
  2013; 23 (12): R527-30
- **Engaging the p53 metabolic brake drives senescence.** *Cell research*
  Jiang, D., Attardi, L. D.
  2013; 23 (6): 739-740
- **Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses** *GENES & DEVELOPMENT*
  Broz, D. K., Mello, S. S., Bieging, K. T., Jiang, D., Dusek, R. L., Brady, C. A., Sidow, A., Attardi, L. D.
  2013; 27 (9): 1016-1031
- **Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses.** *Genes & development*
  Kenzelmann Broz, D., Spano Mello, S., Bieging, K. T., Jiang, D., Dusek, R. L., Brady, C. A., Sidow, A., Attardi, L. D.
  2013; 27 (9): 1016-1031
- **RB goes mitochondrial.** *Genes & development*

Attardi, L. D., Sage, J.
2013; 27 (9): 975-979

- **Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse.** *Oral surgery, oral medicine, oral pathology and oral radiology*
  Kong, C. S., Cao, H., Kwok, S., Nguyen, C. M., Jordan, R. C., Beaudry, V. G., Attardi, L. D., Le, Q.
  2013; 115 (1): 95-103
- **Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse** *ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY*
  Kong, C. S., Cao, H., Kwok, S., Nguyen, C. M., Jordan, R. C., Beaudry, V. G., Attardi, L. D., Quynh-Thu Le, Q. T.
  2013; 115 (1): 95-103
- **Unimpaired Skin Carcinogenesis in Desmoglein 3 Knockout Mice** *PLOS ONE*
  Baron, S., Anabel Hoang, A., Vogel, H., Attardi, L. D.
  2012; 7 (11)
- **Deconstructing p53 transcriptional networks in tumor suppression** *TRENDS IN CELL BIOLOGY*
  Bieging, K. T., Attardi, L. D.
  2012; 22 (2): 97-106
- **Deficiency of the p53/p63 target Perp alters mammary gland homeostasis and promotes cancer** *BREAST CANCER RESEARCH*
  Dusek, R. L., Bascom, J. L., Vogel, H., Baron, S., Borowsky, A. D., Bissell, M. J., Attardi, L. D.
  2012; 14 (2)
- **Roles of p53 and pRB Tumor Suppressor Networks in Human Cancer: Insight from Studies in the Engineered Mouse** *GENETICALLY ENGINEERED MICE FOR CANCER RESEARCH: DESIGN, ANALYSIS, PATHWAYS, VALIDATION AND PRE-CLINICAL TESTING*
  Sage, J., Attardi, L., Van Dyke, T.
  edited by Green, J. E., Ried, T.
  2012: 293–308
- **Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Jiang, D., Brady, C. A., Johnson, T. M., Lee, E. Y., Park, E. J., Scott, M. P., Attardi, L. D.
  2011; 108 (41): 17123-17128
- **The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor** *ONCOGENE*
  Renault, V. M., Thekkat, P. U., Hoang, K. L., WHITE, J. L., Brady, C. A., Broz, D. K., Venturelli, O. S., Johnson, T. M., Oskoui, P. R., Xuan, Z., Santo, E. E., Zhang, M. Q., Vogel, et al
  2011; 30 (29): 3207-3221
- **Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression** *CELL*
  Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., Karnezis, A. N., Attardi, L. D.
  2011; 145 (4): 571-583
- **Desmosomes: new perpetrators in tumour suppression** *NATURE REVIEWS CANCER*
  Dusek, R. L., Attardi, L. D.
  2011; 11 (5): 317-323
- **PERP regulates enamel formation via effects on cell-cell adhesion and gene expression** *JOURNAL OF CELL SCIENCE*
  Jheon, A. H., Mostowfi, P., Snead, M. L., Ihrie, R. A., Sone, E., Pramparo, T., Attardi, L. D., Klein, O. D.
  2011; 124 (5): 745-754
- **Loss of the p53/p63 Regulated Desmosomal Protein Perp Promotes Tumorigenesis** *PLOS GENETICS*
  Beaudry, V. G., Jiang, D., Dusek, R. L., Park, E. J., Knezevich, S., Ridd, K., Vogel, H., Bastian, B. C., Attardi, L. D.
  2010; 6 (10)
- **A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response** *CELL*
  Huarte, M., Guttman, M., Feldser, D., Garber, M., Koziol, M. J., Kenzelmann-Broz, D., Khalil, A. M., Zuk, O., Amit, I., Rabani, M., Attardi, L. D., Regev, A., Lander, et al

2010; 142 (3): 409-419

- **p53 at a glance** *JOURNAL OF CELL SCIENCE*
  Brady, C. A., Attardi, L. D.
  2010; 123 (15): 2527-2532
- **In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models** *CARCINOGENESIS*
  Broz, D. K., Attardi, L. D.
  2010; 31 (8): 1311-1318
- **Loss of the desmosomal component perp impairs wound healing in vivo.** *Dermatology research and practice*
  Beaudry, V. G., Ihrie, R. A., Jacobs, S. B., Nguyen, B., Pathak, N., Park, E., Attardi, L. D.
  2010; 2010: 759731-?
- **Lessons on p53 from Mouse Models** *MOLECULAR BIOLOGY INTELLIGENCE UNIT P53*
  Jiang, D., Attardi, L. D.
  edited by Ayed, A., Hupp, T.
  2010: 19–35
- **Differential PERP Regulation by TP63 Mutants Provides Insight Into AEC Pathogenesis** *AMERICAN JOURNAL OF MEDICAL GENETICS PART A*
  Beaudry, V. G., Pathak, N., Koster, M. I., Attardi, L. D.
  2009; 149A (9): 1952-1957
- **SKP-ing TAp63: Stem Cell Depletion, Senescence, and Premature Aging** *CELL STEM CELL*
  Beaudry, V. G., Attardi, L. D.
  2009; 5 (1): 1-2
- **Loss of the Desmosomal Protein Perp Enhances the Phenotypic Effects of Pemphigus Vulgaris Autoantibodies** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
  Nguyen, B., Dusek, R. L., Beaudry, V. G., Marinkovich, M. P., Attardi, L. D.
  2009; 129 (7): 1710-1718
- **Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects** *NATURE GENETICS*
  McGowan, K. A., Li, J. Z., Park, C. Y., Beaudry, V., Tabor, H. K., Sabnis, A. J., Zhang, W., Fuchs, H., de Angelis, M. H., Myers, R. M., Attardi, L. D., Barsh, G. S.
  2008; 40 (8): 963-970
- **The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation** *MOLECULAR CELL*
  Basak, S., Jacobs, S. B., Krieg, A. J., Pathak, N., Zeng, Q., Kaldis, P., Giaccia, A. J., Attardi, L. D.
  2008; 30 (3): 303-314
- **Genetics of dark skin: new genes, new pathways**
  Barsh, G., McGowan, K., van Raamsdonk, C., Attardi, L., Bastian, B.
  WILEY-BLACKWELL.2008: 248–48
- **Mutations in ribosomal proteins cause p53-mediated dark skin** *International Investigative Dermatology Meeting*
  McGowan, K., Li, J. Z., Beaudry, V., Tabor, H. K., Sabnis, A. J., Zhang, W., Fuchs, H., d'Angelis, M. H., Myers, R. M., Attardi, L. D., Barsh, G. S.
  NATURE PUBLISHING GROUP.2008: S110–S110
- **Knockin mice expressing a Chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Johnson, T. M., Meade, K., Pathak, N., Marques, M. R., Attardi, L. D.
  2008; 105 (4): 1215-1220
- **Siva is an apoptosis-selective p53 target gene important for neuronal cell death** *CELL DEATH AND DIFFERENTIATION*
  Jacobs, S. B., Basak, S., Murray, J. I., Pathak, N., Attardi, L. D.
  2007; 14 (7): 1374-1385
- **A healthy tan?** *New England journal of medicine*
  Barsh, G., Attardi, L. D.

2007; 356 (21): 2208-2210

- **Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage** *CANCER RESEARCH*
  Wijnhoven, S. W., Speksnijder, E. N., Liu, X., Zwart, E., vanOostrom, C. T., Beems, R. B., Hoogervorst, E. M., Schaap, M. M., Attardi, L. D., Jacks, T., van Steeg, H., Jonkers, J., de Vries, et al
  2007; 67 (10): 4648-4656
- **P63, cell adhesion and survival** *CELL CYCLE*
  Carroll, D. K., Brugge, J. S., Attardi, L. D.
  2007; 6 (3): 255-261
- **Adult mice lacking the p53/p63 target gene Perp are not predisposed to spontaneous tumorigenesis but display features of ectodermal dysplasia syndromes** *CELL DEATH AND DIFFERENTIATION*
  Ihrie, R. A., Bronson, R. T., Attardi, L. D.
  2006; 13 (9): 1614-1618
- **Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice** *CELL DEATH AND DIFFERENTIATION*
  Johnson, T. M., Attardi, L. D.
  2006; 13 (6): 902-908
- **Genome-wide analysis of p53 under hypoxic conditions** *MOLECULAR AND CELLULAR BIOLOGY*
  Hammond, E. M., Mandell, D. J., Salim, A., Krieg, A. J., Johnson, T. M., Shirazi, H. A., Attardi, L. D., Giaccia, A. J.
  2006; 26 (9): 3492-3504
- **Dissecting p53 tumor suppressor function using transactivation mutant knock-in mice**
  Attardi, L. D., Johnson, T.
  AMER ASSOC CANCER RESEARCH.2006
- **The requirement for Perp in postnatal viability and epithelial integrity reflects an intrinsic role in stratified epithelia** *JOURNAL OF INVESTIGATIVE DERMATOLOGY*
  Marques, M. R., Ihrie, R. A., Horner, J. S., Attardi, L. D.
  2006; 126 (1): 69-73
- **Probing p53 biological functions through the use of genetically engineered mouse models** *MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS*
  Attardi, L. D., Donehower, L. A.
  2005; 576 (1-2): 4-21
- **Mice lacking the p53/p63 target gene perp are resistant to papilloma development** *CANCER RESEARCH*
  Marques, M. R., Horner, J. S., Ihrie, R. A., Bronson, R. T., Attardi, L. D.
  2005; 65 (15): 6551-6556
- **A new Perp in the lineup - Linking p63 and desmosomal adhesion** *CELL CYCLE*
  Ihrie, R. A., Attardi, L. D.
  2005; 4 (7): 873-876
- **Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer** *BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS*
  Artandi, S. E., Attardi, L. D.
  2005; 331 (3): 881-890
- **p53(QS) - An old mutant teaches us new tricks** *CELL CYCLE*
  Johnson, T. M., Attardi, L. D.
  2005; 4 (6): 731-734
- **Perp is a p63-regulated gene essential for epithelial integrity** *CELL*
  Ihrie, R. A., Marques, M. R., Nguyen, B. T., Horner, J. S., Papazoglu, C., Bronson, R. T., Mills, A. A., Attardi, L. D.
  2005; 120 (6): 843-856
- **Opinion - The role of apoptosis in cancer development and treatment response** *NATURE REVIEWS CANCER*

Brown, J. M., Attardi, L. D.
2005; 5 (3): 231-237

- **The p53(QS) transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality** *NATURE GENETICS*
  Johnson, T. M., Hammond, E. M., Giaccia, A., Attardi, L. D.
  2005; 37 (2): 145-152
- **The role of p53-mediated apoptosis as a crucial anti-tumor response to genomic instability: lessons from mouse models** *MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS*
  Attardi, L. D.
  2005; 569 (1-2): 145-157
- **Developmental context determines latency of MYC-induced tumorigenesis** *PLOS BIOLOGY*
  Beer, S., Zetterberg, A., Ihrie, R. A., McTaggart, R. A., Yang, Q. W., Bradon, N., Arvanitis, C., Attardi, L. D., Feng, S., Ruebner, B., Cardiff, R. D., Felsher, D. W.
  2004; 2 (11): 1785-1798
- **Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389** *MOLECULAR AND CELLULAR BIOLOGY*
  Bruins, W., Zwart, E., Attardi, L. D., Iwakuma, T., Hoogervorst, E. M., Beems, R. B., Miranda, B., van Oostrom, C. T., Van den Berg, J., van den Aardweg, G. J., Lozano, G., van Steeg, H., Jacks, et al
  2004; 24 (20): 8884-8894
- **Perp-etrating p53-dependent apoptosis** *CELL CYCLE*
  Ihrie, R. A., Attardi, L. D.
  2004; 3 (3): 267-269
- **Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer** *ONCOGENE*
  Attardi, L. D., de Vries, A., Jacks, T.
  2004; 23 (4): 973-980
- **Conquering the complexity of p53** *NATURE GENETICS*
  Attardi, L. D., DePinho, R. A.
  2004; 36 (1): 7-8
- **Multiple response elements and differential p53 binding control perp expression during apoptosis** *MOLECULAR CANCER RESEARCH*
  Reczek, E. E., Flores, E. R., Tsay, A. S., Attardi, L. D., Jacks, T.
  2003; 1 (14): 1048-1057
- **Perp is a mediator of p53-dependent apoptosis in diverse cell types** *CURRENT BIOLOGY*
  Ihrie, R. A., Reczek, E., Horner, J. S., Khachatrian, L., Sage, J., Jacks, T., Attardi, L. D.
  2003; 13 (22): 1985-1990
- **Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization** *GENES & DEVELOPMENT*
  Sage, J., Mulligan, G. J., Attardi, L. D., Miller, A., Chen, S. Q., Williams, B., Theodorou, E., Jacks, T.
  2000; 14 (23): 3037-3050
- **PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family** *GENES & DEVELOPMENT*
  Attardi, L. D., Reczek, E. E., Cosmas, C., Demicco, E. G., McCurrach, M. E., Lowe, S. W., Jacks, T.
  2000; 14 (6): 704-718
- **The role of p53 in tumour suppression: lessons from mouse models** *CELLULAR AND MOLECULAR LIFE SCIENCES*
  Attardi, L. D., Jacks, T.
  1999; 55 (1): 48-63
- **Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis** *CELL GROWTH & DIFFERENTIATION*
  Jones, J. M., Attardi, L., Godley, L. A., Laucirica, R., Medina, D., Jacks, T., Varmus, H. E., Donehower, L. A.
  1997; 8 (8): 829-838
- **Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis** *EMBO JOURNAL*

Attardi, L. D., Lowe, S. W., Brugarolas, J., Jacks, T.
1996; 15 (14): 3693-3701

- **Transcriptional Activation by p53, but not Induction of the p21 Gene, is Essential for Oncogene-Mediated Apoptosis** *Embo J*
  Attardi, L.D., S.W. Lowe, J. Brugarolas, T. Jacks
  1996; 15

- **A SUBSET OF P53-DEFICIENT EMBRYOS EXHIBIT EXENCEPHALY** *NATURE GENETICS*
  Sah, V. P., Attardi, L. D., Mulligan, G. J., Williams, B. O., Bronson, R. T., Jacks, T.
  1995; 10 (2): 175-180

- **ASSEMBLY OF RECOMBINANT TFIID REVEALS DIFFERENTIAL COACTIVATOR REQUIREMENTS FOR DISTINCT TRANSCRIPTIONAL ACTIVATORS** *CELL*
  Chen, J. L., Attardi, L. D., Verrijzer, C. P., Yokomori, K., Tjian, R.
  1994; 79 (1): 93-105